Biocon Biologics  /  Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index

Biocon (including Biocon Biologics) improved its Environmental, Social and Governance (ESG) score to 52 up from 45 in 2021 on the Dow Jones Sustainability™ Emerging Markets Index.

The Dow Jones Sustainability™ Emerging Markets Index comprises emerging-market sustainability leaders as identified by S&P Global through the Corporate Sustainability Assessment (CSA). It aims to represent the top 10% of the largest 800 companies in 20 emerging markets based on long-term economic, environmental and social criteria.

Biocon’s Score Card:
  • Biocon has secured a Total Sustainability Score of 52 as against 45 in 2021. The industry mean was 14.
  • In Governance Dimension Biocon’s score is 63, a big improvement from 50 in 2021.
  • In Environmental Dimension, Biocon scored 50 versus 45 in 2021.
  • In Social Dimension, the company scored 43, up from 39 in 2021.

S&P provides ESG Scores based on a stringent evaluation and screening process. On the basis of their performance, companies receive scores ranging from 0 to 100 and percentile rankings for approximately 20 financially relevant sustainability criteria across economic, environmental and social dimensions.

Biocon’s responsible business practices, which embed social impact in all that it does, includes effectively managing environmental, social and governance (ESG) matters. The company believes business has a key role to play in solving social challenges, and it works to do so by widening affordable access to essential and lifesaving medicines, supporting and developing the skills of its employees, and investing in communities to help more people share in the benefits of economic growth.

Operations at Biocon and Biocon Biologics have been designed to enable environmental sustainability with a low carbon footprint, complete recycling of wastewater and maximum use of green power. Both companies are committed to diversity and inclusion at the workplace and are consistently endeavoring to create a collaborative and empowering work culture, in pursuit of building businesses that make a meaningful social impact. Globally benchmarked standards of governance have been established to build an environment of trust, transparency and accountability.

While the principles of ESG — operating responsibly and sustainably and caring for people and communities — have been ingrained in Biocon’s DNA since inception, the company is evolving and expanding its sustainability reporting by capturing its environmental management, social impact, and corporate governance practices to enhance transparency on non-financial performance. Both Biocon and Biocon Biologics are committed to provide insights into their ESG performance to their stakeholders.

Hope. Now within reach
Meeting unmet patient needs
Research Saves Lives
First to Launch an Interchangeable Biosimilar in U.S.
First to Launch an Interchangeable Biosimilar in U.S.
Biocon Certified as a Great Place to Work® : DEI
Biocon Certified as a Great Place to Work® : DEI
Strategic Alliance with Serum Institute to Impact Global Health
Strategic Alliance with Serum Institute to Impact Global Health
Biocon Biologics to Acquire Viatris Global Biosimilars Assets
Biocon Biologics to Acquire Viatris’ Global Biosimilars Assets in Transformational Deal
buy twitter followers